Human Leukocyte Antigen Mismatch and Other Factors Affecting Cryopreserved Allograft Valve Function
AbstractThe causes of cryopreserved allograft heart valve degeneration are poorly understood. We investigated HLA mismatch and other factors implicated in allograft valve degeneration. For this study we recruited 110 adult recipients of allograft heart valves who underwent surgery between June 1998 and March 2003 in the state of Victoria, Australia. Recipients and donors were HLA typed using serological and molecular methods. Valve function at most recent echocardiographic follow-up was examined for an association with the following variables using univariate and multivariate methods: HLA-A,-B, and -DR donor-recipient mismatch; HLA class I mismatch; total HLA mismatch; valve ischemic time; recipient age; donor age; ABO blood group donor-recipient match; and allograft size. Mean recipient age was 45 years (18-75 years), 75% were men. Seventy-four pulmonary (62 Ross procedure) and 36 aortic allografts were examined. Median valve ischemic time was 31 hours, range 20-48 hours. Echocardiographic follow-up was complete at a mean of 41 (±18) months, range 6-85 months. At univariate analysis longer ischemic time and younger recipient age were associated with valve dysfunction. HLA-A, -B, or DR mismatch, HLA class I mismatch, total HLA mismatch, donor age, ABO mismatch, and allograft size were not associated with valve dysfunction. Only younger recipient age remained significant at multivariate analysis. In conclusion, longer ischemic times and younger patient age predicted valve dysfunction at a mean of 3 years follow-up. Recipient age remained the strongest predictor of valve dysfunction. These results indicate that allograft ischemic times should be minimized.
Albert JD, Bishop DA, Fullerton DA, et al. 1993. Conduit reconstruction of the right ventricular outflow tract. Lessons learned in a twelve-year experience. J Thorac Cardiovasc Surg 106:228-35.nBaskett RJ, Nanton MA, Warren AE, Ross D. 2003. Human leukocyte antigen-DR and ABO mismatch are associated with accelerated homograft valve failure in children: implications for therapeutic interventions. J Thorac Cardiovasc Surg 126:232-9.nBechtel JF, Bartels C, Schmidtke C, et al. 2001. Does histocompatibility affect homograft valve function after the Ross procedure? Circulation 104(suppl 1):125-8.nDaenen W, Gewillig M. 1997. Factors influencing medium-term performance of right-sided cryopreserved homografts. J Heart Valve Dis 6:347-54.nDignan R, O'Brien M, Hogan P, et al. 2000. Influence of HLA matching and associated factors on aortic valve homograft function. J Heart Valve Dis 9:504-11.nDignan R, O'Brien M, Hogan P, et al. 2003. Aortic valve allograft structural deterioration is associated with a subset of antibodies to human leukocyte antigens. J Heart Valve Dis 12:382-90.nForbess JM, Shah AS, St Louis JD, Jaggers JJ, Ungerleider RM. 2001. Cryopreserved homografts in the pulmonary position: determinants of durability. Ann Thorac Surg 71:54-9.nFrater RW, Furlong P, Cosgrove DM, et al. Long-term durability and patient functional status of the Carpentier-Edwards Perimount pericardial bioprosthesis in the aortic position. J Heart Valve Dis 7:48-53.nGall KL, Smith SE, Willmette CA, O'Brien MF. 1998. Allograft heart valve viability and valve-processing variables. Ann Thorac Surg 65:1032-8.nGerestein CG, Takkenberg JJ, Oei FB, et al. 2001. Right ventricular outflow tract reconstruction with an allograft conduit. Ann Thorac Surg 71:911-8.nHawkins JA, Breinholt JP, Lambert LM, McGough CC, Shaddy RE. 2000. Class I and class II anti-HLA antibodies after implantation of cryopreserved allograft material in pediatric patients. J Thorac Cardiovasc Surg 119:324-30.nHoekstra F, Knoop C, Vaessen L, et al. 1996. Donor-specific cellular immune response against human cardiac valve allografts. J Thorac Cardiovasc Surg 112:281-6.nKurz B, Steiert I, Heuchert G, Müller CA. 1999. New high resolution typing strategy for HLA-A locus alleles based on dye terminator sequencing of haplotypic group-specific PCR-amplicons of exon 2 and exon 3. Tissue Antigens 53:81-96.nLund O, Chandrasekaran V, Grocott-Mason R, et al. 1999. Primary aortic valve replacement with allografts over twenty-five years: valve-related and procedure-related determinants of outcome. J Thorac Cardiovasc Surg 117:77-90.nMiller SA, Dykes DD, Polesky HF. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215.nMittal KK, Mickey MR, Singal DP, et al. 1968. Serotyping for homo-transplantation. 18. Refinement of microdroplet lymphocyte cytotoxicity test. Transplantation 6:913-27.nNiwaya K, Knott-Craig CJ, Lane MM, Chandrasekaren K, Overhold ED, Elkins RC. 1999. Cryopreserved homograft valves in the pulmonary position: risk analysis for intermediate-term failure. J Thorac Cardiovasc Surg 117:141-6.nO'Brien MF, Finney RS, Stafford EG, et al. 1995. Root replacement for all allograft aortic valves: preferred technique or too radical? Ann Thorac Surg 60(suppl 2):S87-91.nO'Brien MF, Harrocks S, Stafford EG, et al. 2001. The homograft aortic valve: a 29-year, 99.3% follow up of 1,022 valve replacements. J Heart Valve Dis 10:334-44.nPalka P, Harrocks S, Lange A, et al. 2002. Primary aortic valve replacement with cryopreserved aortic allograft: an echocardiographic follow-up study of 570 patients. Circulation 105:61-6.nSchorn K, Yankah AC, Alexi-Meskhishvili V, et al. 1997. Risk factors for early degeneration of allografts in pulmonary circulation. Eur J Cardiothorac Surg 11:62-9.nSmith JD, Horninck PI, Rasmi N, et al. 1998. Effect of HLA mismatching and antibody status on "homovital" aortic valve homograft performance. Ann Thorac Surg 66:212-5.nTweddell JS, Pelech AN, Frommelt PC, et al. 2000. Factors affecting longevity of homograft valves used in right ventricular outflow tract reconstruction for congenital heart disease. Circulation 102(suppl 3):III130-5.nYacoub M, Rasmi NR, Sundt TM, et al. 1995. Fourteen-year experience with homovital homografts for aortic valve replacement. J Thorac Cardiovasc Surg 110:186-93.nYankah AC, Alexi-Meskhishvili V, Weng Y, et al. 1995. Accelerated degeneration of allografts in the first two years of life. Ann Thorac Surg 60(suppl 2):S71-6.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).